抗血管生成剂在治疗非小细胞肺癌中的作用  

Application of antiangiogenic agents in the treatment of non-small cell lung cancer

作　　者：李雪峰 金艺凤[1] LI Xue-feng(Yijishan hospital of Wannan Medical college,Wuhu,Anhui,241000,China)

机构地区：[1]皖南医学院弋矶山医院,安徽芜湖241000

出　　处：《齐齐哈尔医学院学报》2020年第1期93-95,共3页Journal of Qiqihar Medical University

摘　　要：血管生成是一种极其复杂的生物学过程,它在各种肿瘤生长和转移中起着重要作用,其中包括非小细胞肺癌。一些研究发现,肺癌患者中血管生成因子高表达者比低表达者的平均生存期短,促使抗血管生成药物在治疗肺癌领域被广泛研究和应用。贝伐单抗是首次被批准用于晚期非小细胞肺癌一线治疗的血管生成抑制剂,且仅限于病理类型腺癌患者。之后,一些其他抗血管生成药物被研究用于治疗非小细胞肺癌,包括VEGFR抗体、小分子酪氨酸酶抑制剂等。最近的研究发现,两种新的抗血管生成剂Ramucirumab和Nidanib在二线治疗中具有显著的生存益处,安罗替尼是国内非小细胞肺癌的三线治疗药物。本综述重点介绍非小细胞肺癌(NSCLC)治疗中抗血管生成药物的应用现状。Angiogenesis is an extremely complex biological process,which plays an important role in the growth and metastasis of various tumors,non-small cell lung cancer(NSCLC)was included.Some studies have found that the average survival time of the patients with high expression of antiangiogenic factors is shorter than those of the patients with low expression of antiangiogenic factors,which has prompted the widespread research and application of anti-angiogenic drugs in the treatment of lung cancer.Bevacizumab is the first angiogenesis inhibitor which was approved for first-line treatment of advanced non-small cell lung cancer and is limited to patients with pathological types of adenocarcinoma.Since then,several other anti-angiogenic drugs have been developed to treat non-small cell lung cancer,including VGEFR antibodies,small molecule tyrosinase inhibitors.Recent studies have found that two new anti-angiogenic agents(Ramucirumab and Nidanib)have significant benefits for survival in second-line therapy,and Anlotinib is a third-line drug for non-small cell lung cancer.This review focuses on the current status of anti-angiogenic drugs therapy in NSCLC.

关 键 词：肺癌 抗血管生成 血管内皮生长因子 靶向治疗 

分 类 号：R734[医药卫生—肿瘤]